{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T17:06:59Z","timestamp":1793639219784,"version":"4.5.1"},"reference-count":85,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T00:00:00Z","timestamp":1770076800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Gansu Provincial Department of Science and Technology","award":["23YFFA0035"],"award-info":[{"award-number":["23YFFA0035"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>Triple-negative breast cancer (TNBC) accounts for 15\u201320% of invasive breast cancers and represents a highly heterogeneous, aggressive subtype with poor prognosis and limited treatment options, necessitating the identification of novel therapeutic targets to improve clinical outcomes. Trophoblast cell-surface antigen 2 (Trop2), a calcium signal transducer, is frequently overexpressed in TNBC (approximately 88% of cases) while exhibiting minimal expression in normal tissues. Its overexpression is significantly associated with tumor invasion, metastasis, and unfavorable prognosis. Antibody\u2013drug conjugates (ADCs) targeting Trop2 have demonstrated significant clinical potential. This article systematically reviews the clinical research progress of Trop2-targeted ADCs, aiming to provide evidence-based insights for improving the prognosis of TNBC patients.<\/jats:p>","DOI":"10.3390\/curroncol33020092","type":"journal-article","created":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T12:46:11Z","timestamp":1770122771000},"page":"92","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Trop2-Based Antibody\u2013Drug Conjugates: Emerging Strategy and Progress in Triple-Negative Breast Cancer Therapy"],"prefix":"10.3390","volume":"33","author":[{"given":"Tong","family":"Li","sequence":"first","affiliation":[{"name":"The First Clinical Medical College, Lanzhou University, No. 199 Donggang West Road, Lanzhou 730000, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Oncology, The First Hospital of Lanzhou University, No. 1 Donggang West Road, Lanzhou 730000, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongxia","family":"Dang","sequence":"additional","affiliation":[{"name":"The First Clinical Medical College, Lanzhou University, No. 199 Donggang West Road, Lanzhou 730000, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yilin","family":"Lin","sequence":"additional","affiliation":[{"name":"The First Clinical Medical College, Lanzhou University, No. 199 Donggang West Road, Lanzhou 730000, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaotong","family":"Li","sequence":"additional","affiliation":[{"name":"The First Clinical Medical College, Lanzhou University, No. 199 Donggang West Road, Lanzhou 730000, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoling","family":"Ling","sequence":"additional","affiliation":[{"name":"Department of Oncology, The First Hospital of Lanzhou University, No. 1 Donggang West Road, Lanzhou 730000, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,2,3]]},"reference":[{"key":"ref_1","first-page":"10","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel","year":"2025","journal-title":"CA A Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1186\/s13046-022-02476-1","article-title":"Heterogeneity of triple negative breast cancer: Current advances in subtyping and treatment implications","volume":"41","author":"Asleh","year":"2022","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1056\/NEJMra1001389","article-title":"Triple-negative breast cancer","volume":"363","author":"Foulkes","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s13058-020-01296-5","article-title":"Triple-negative breast cancer molecular subtyping and treatment progress","volume":"22","author":"Yin","year":"2020","journal-title":"Breast Cancer Res."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1002\/dvdy.24242","article-title":"Trop2: From development to disease","volume":"244","author":"McDougall","year":"2015","journal-title":"Dev. Dyn."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"4197","DOI":"10.1158\/1078-0432.CCR-15-1701","article-title":"Trop-2 induces tumor growth through AKT and determines sensitivity to AKT inhibitors","volume":"22","author":"Guerra","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"6136","DOI":"10.18632\/oncotarget.6733","article-title":"Trop2 is overexpressed in gastric cancer and predicts poor prognosis","volume":"7","author":"Zhao","year":"2015","journal-title":"Oncotarget"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"28989","DOI":"10.18632\/oncotarget.25615","article-title":"The emergence of trophoblast cell-surface antigen 2 (TROP-2) as a novel cancer target","volume":"9","author":"Goldenberg","year":"2018","journal-title":"Oncotarget"},{"key":"ref_9","first-page":"759","article-title":"Trop2 is a potential biomarker for the promotion of EMT in human breast cancer","volume":"40","author":"Zhao","year":"2018","journal-title":"Oncol. Rep."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"6540","DOI":"10.18632\/oncotarget.27299","article-title":"Correction: TROP2 promotes proliferation, migration and metastasis of gallbladder cancer cells by regulating PI3K\/AKT pathway and inducing EMT","volume":"10","author":"Li","year":"2019","journal-title":"Oncotarget"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1038\/s41573-023-00709-2","article-title":"Antibody-drug conjugates come of age in oncology","volume":"22","author":"Dumontet","year":"2023","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/s41571-023-00850-2","article-title":"Exploring the next generation of antibody-drug conjugates","volume":"21","author":"Tsuchikama","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1056\/NEJMoa2028485","article-title":"Sacituzumab govitecan in metastatic triple-negative breast cancer","volume":"384","author":"Bardia","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Cheng, Y., Yuan, X., Tian, Q., Huang, X., Chen, Y., Pu, Y., Long, H., Xu, M., Ji, Y., and Xie, J. (2022). Preclinical profiles of SKB264, a novel anti-TROP2 antibody conjugated to topoisomerase inhibitor, demonstrated promising antitumor efficacy compared to IMMU-132. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.951589"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"4405","DOI":"10.1158\/1078-0432.CCR-25-1388","article-title":"FDA Approval Summary: Datopotamab Deruxtecan-dlnk for Treatment of Patients with Unresectable or Metastatic, HR-Positive, HER2-Negative Breast Cancer","volume":"31","author":"Royce","year":"2025","journal-title":"Clin. Cancer Res."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.21037\/atm-22-5976","article-title":"A literature review of the promising future of TROP2: A potential drug therapy target","volume":"10","author":"Wen","year":"2022","journal-title":"Ann. Transl. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.bbcan.2009.08.001","article-title":"Trop2: A possible therapeutic target for late stage epithelial carcinomas","volume":"1796","author":"Cubas","year":"2009","journal-title":"Biochim. Biophys. Acta (BBA)-Rev. Cancer"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1101\/gad.196451.112","article-title":"Regulated proteolysis of Trop2 drives epithelial hyperplasia and stem cell self-renewal via \u03b2-catenin signaling","volume":"26","author":"Stoyanova","year":"2012","journal-title":"Genes Dev."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/s40364-024-00633-6","article-title":"Trop2-targeted therapy in breast cancer","volume":"12","author":"Hu","year":"2024","journal-title":"Biomark. Res."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"108296","DOI":"10.1016\/j.pharmthera.2022.108296","article-title":"Advances in Trop2-targeted therapy: Novel agents and opportunities beyond breast cancer","volume":"239","author":"Liu","year":"2022","journal-title":"Pharmacol. Ther."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Jeon, Y., Jo, U., Hong, J., Gong, G., and Lee, H.J. (2022). Trophoblast cell-surface antigen 2 (TROP2) expression in triple-negative breast cancer. BMC Cancer, 22.","DOI":"10.1186\/s12885-022-10076-7"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1002\/ptr.8407","article-title":"Unlocking Natural Potential: Antibody-Drug Conjugates with Naturally Derived Payloads for Cancer Therapy","volume":"39","author":"Jiang","year":"2025","journal-title":"Phytother. Res."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1517\/14712598.2012.693473","article-title":"Antibody-drug conjugates\u2014A perfect synergy","volume":"12","author":"Adair","year":"2012","journal-title":"Expert. Opin. Biol. Ther."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"22496","DOI":"10.18632\/oncotarget.4318","article-title":"Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC)","volume":"6","author":"Goldenberg","year":"2015","journal-title":"Oncotarget"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1016\/j.annonc.2021.03.005","article-title":"Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: Final safety and efficacy results from the phase I\/II IMMU-132-01 basket trial","volume":"32","author":"Bardia","year":"2021","journal-title":"Ann. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Tong, Y., Fan, X., Liu, H., and Liang, T. (2024). Advances in Trop-2 targeted antibody-drug conjugates for breast cancer: Mechanisms, clinical applications, and future directions. Front. Immunol., 15.","DOI":"10.3389\/fimmu.2024.1495675"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1158\/1078-0432.CCR-24-1525","article-title":"The Mode of Action and Clinical Outcomes of Sacituzumab Govitecan in Solid Tumors","volume":"31","author":"Tolaney","year":"2025","journal-title":"Clin. Cancer Res."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1093\/jnci\/djz035","article-title":"Antibody-Drug Conjugate-Based Therapeutics: State of the Science","volume":"111","author":"Birrer","year":"2019","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1016\/j.annonc.2021.06.002","article-title":"Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer","volume":"32","author":"Bardia","year":"2021","journal-title":"Ann. Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"100497","DOI":"10.1016\/j.esmoop.2022.100497","article-title":"The European Medicines Agency review of sacituzumab govitecan for the treatment of triple-negative breast cancer","volume":"7","author":"Michaleas","year":"2022","journal-title":"ESMO Open"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"e545","DOI":"10.1016\/j.clbc.2024.04.010","article-title":"Cost-effectiveness of sacituzumab govitecan versus single-agent chemotherapy for patients with metastatic triple-negative breast cancer in China","volume":"24","author":"Wang","year":"2024","journal-title":"Clin. Breast Cancer"},{"key":"ref_32","first-page":"S1680","article-title":"LBA20 Primary results from ASCENT-03: A randomized phase III study of sacituzumab govitecan (SG) vs chemotherapy (chemo) in patients (pts) with previously untreated advanced triple-negative breast cancer (TNBC) who are unable to receive PD-(L) 1 inhibitors (PD-[L] 1i)","volume":"36","author":"Bardia","year":"2025","journal-title":"Ann. Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1200\/JCO.2025.43.16_suppl.511","article-title":"A phase 2 study of response-guided neoadjuvant sacituzumab govitecan and pembrolizumab (SG\/P) in patients with early-stage triple-negative breast cancer: Results from the NeoSTAR trial","volume":"43","author":"Abelman","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"S664","DOI":"10.1016\/j.annonc.2022.07.1860","article-title":"276TiP ASCENT-04\/KEYNOTE-D19: Phase III study of sacituzumab govitecan (SG) plus pembrolizumab (pembro) vs treatment of physician\u2019s choice (TPC) plus pembro in first-line (1L) programmed death-ligand 1-positive (PD-L1+) metastatic triple-negative breast cancer (mTNBC)","volume":"33","author":"Tolaney","year":"2022","journal-title":"Ann. Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"103203","DOI":"10.1016\/j.esmoop.2024.103203","article-title":"181O Interim analysis (IA) of the atezolizumab (atezo)+ sacituzumab govitecan (SG) arm in patients (pts) with triple-negative breast cancer (TNBC) in MORPHEUS-pan BC: A phase Ib\/II study of multiple treatment (tx) combinations in pts with locally advanced\/metastatic BC (LA\/mBC)","volume":"9","author":"Schmid","year":"2024","journal-title":"ESMO Open"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"TPS1106","DOI":"10.1200\/JCO.2021.39.15_suppl.TPS1106","article-title":"Saci-IO TNBC: Randomized phase II trial of sacituzumab govitecan (SG)+\/-pembrolizumab in PD-L1\u2013metastatic triple-negative breast cancer (mTNBC)","volume":"39","author":"Keenan","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.annonc.2024.05.536","article-title":"Challenging immune exhaustion in early recurrent triple-negative breast cancer: Pitfalls and hopes","volume":"35","author":"Tarantino","year":"2024","journal-title":"Ann. Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"TPS1140","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS1140","article-title":"Phase I\/II study of stereotactic radiation and sacituzumab govitecan with zimberelimab in the management of metastatic triple negative breast cancer with brain metastases","volume":"42","author":"Ahmed","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"2917","DOI":"10.1158\/1078-0432.CCR-24-0428","article-title":"Antibody\u2013drug conjugate sacituzumab govitecan enables a sequential TOP1\/PARP inhibitor therapy strategy in patients with breast cancer","volume":"30","author":"Bardia","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"101390","DOI":"10.1016\/j.esmoop.2023.101390","article-title":"201P trilaciclib combined with sacituzumab govitecan (SG) in metastatic triple-negative breast cancer (mTNBC): Preliminary phase II results","volume":"8","author":"Seneviratne","year":"2023","journal-title":"ESMO Open"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1200\/JCO.2025.43.16_suppl.1094","article-title":"Results of a phase I study of alpelisib and sacituzumab govitecan (SG) in patients with HER2-negative metastatic breast cancer (MBC)","volume":"43","author":"Sharma","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1146\/annurev-med-071322-065903","article-title":"Leveraging TROP2 Antibody-Drug Conjugates in Solid Tumors","volume":"75","author":"Nelson","year":"2024","journal-title":"Annu. Rev. Med."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1158\/1535-7163.MCT-21-0206","article-title":"Datopotamab Deruxtecan, a Novel TROP2-directed Antibody-drug Conjugate, Demonstrates Potent Antitumor Activity by Efficient Drug Delivery to Tumor Cells","volume":"20","author":"Okajima","year":"2021","journal-title":"Mol. Cancer Ther."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"4678","DOI":"10.1200\/JCO.23.00059","article-title":"First-in-Human, Phase I Dose-Escalation and Dose-Expansion Study of Trophoblast Cell-Surface Antigen 2-Directed Antibody-Drug Conjugate Datopotamab Deruxtecan in Non-Small-Cell Lung Cancer: TROPION-PanTumor01","volume":"41","author":"Shimizu","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1200\/JCO.23.01909","article-title":"Datopotamab Deruxtecan in Advanced or Metastatic HR+\/HER2- and Triple-Negative Breast Cancer: Results From the Phase I TROPION-PanTumor01 Study","volume":"42","author":"Bardia","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"S337","DOI":"10.1016\/j.annonc.2023.09.556","article-title":"379MO Datopotamab deruxtecan (Dato-DXd)+ durvalumab (D) as first-line (1L) treatment for unresectable locally advanced\/metastatic triple-negative breast cancer (a\/mTNBC): Updated results from BEGONIA, a phase Ib\/II study","volume":"34","author":"Schmid","year":"2023","journal-title":"Ann. Oncol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1200\/JCO.24.00920","article-title":"Datopotamab deruxtecan versus chemotherapy in previously treated inoperable\/metastatic hormone receptor\u2013positive human epidermal growth factor receptor 2\u2013negative breast cancer: Primary results from TROPION-Breast01","volume":"43","author":"Bardia","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_48","unstructured":"FDA (2025, July 30). FDA Approves Datopotamab Deruxtecan-Dlnk for Unresectable or Metastatic, HR-Positive, HER2-Negative Breast Cancer, Available online: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-datopotamab-deruxtecan-dlnk-unresectable-or-metastatic-hr-positive-her2-negative-breast."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"S1681","DOI":"10.1016\/j.annonc.2025.09.031","article-title":"LBA21 Datopotamab deruxtecan (Dato-DXd) vs chemotherapy (CT) in patients (pts) with locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC) who are not candidates for PD-(L) 1 inhibitor therapy: Primary results from the randomised, phase 3 TROPION-Breast02 trial","volume":"36","author":"Dent","year":"2025","journal-title":"Ann. Oncol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"103282","DOI":"10.1016\/j.esmoop.2024.103282","article-title":"261TiP TROPION-Breast05: Phase (Ph) III study of datopotamab deruxtecan (Dato-DXd)\u00b1durvalumab (D) vs chemotherapy (CT)+ pembrolizumab (pembro) in patients (pts) with PD-L1+ locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC)","volume":"9","author":"Schmid","year":"2024","journal-title":"ESMO Open"},{"key":"ref_51","first-page":"1","article-title":"TROPION-Breast04: A phase 3 study of neoadjuvant datopotamab deruxtecan (Dato-DXd)+ durvalumab followed by adjuvant durvalumab vs standard of care in treatment-na\u00efve early-stage triple negative and HR-low\/HER2\u2013breast cancer","volume":"17","author":"Loibl","year":"2025","journal-title":"Ther. Adv. Med. Oncol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"17588359241248336","DOI":"10.1177\/17588359241248336","article-title":"TROPION-Breast03: A randomized phase III global trial of datopotamab deruxtecan\u00b1durvalumab in patients with triple-negative breast cancer and residual invasive disease at surgical resection after neoadjuvant therapy","volume":"16","author":"Bardia","year":"2024","journal-title":"Ther. Adv. Med. Oncol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"P2-17-03","DOI":"10.1158\/1538-7445.SABCS22-P2-17-03","article-title":"Abstract P2-17-03: Preclinical study of trastuzumab deruxtecan (T-Dxd; DS-8201a) in combination with DNA damage response pathway inhibitors in HER2-low\/hormone receptor negative breast cancer patient-derived xenograft models","volume":"83","author":"Guo","year":"2023","journal-title":"Cancer Res."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"TPS3659","DOI":"10.1200\/JCO.2020.38.15_suppl.TPS3659","article-title":"SKB264 ADC: A first-in-human study of SKB264 in patients with locally advanced unresectable\/metastatic solid tumors who are refractory to available standard therapies","volume":"38","author":"Liu","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"OT1-03-02","DOI":"10.1158\/1538-7445.SABCS22-OT1-03-02","article-title":"Abstract OT1-03-02: Efficacy and safety of SKB264 for previously treated metastatic triple negative breast cancer in Phase 2 study","volume":"83","author":"Yin","year":"2023","journal-title":"Cancer Res."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1038\/s41591-025-03630-w","article-title":"Sacituzumab tirumotecan in previously treated metastatic triple-negative breast cancer: A randomized phase 3 trial","volume":"31","author":"Yin","year":"2025","journal-title":"Nat. Med."},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Crescioli, S., Kaplon, H., Wang, L., Visweswaraiah, J., Kapoor, V., and Reichert, J.M. (2025, January 19). Antibodies to watch in 2025. Proceedings of the Mabs 2025, Detroit, MI, USA.","DOI":"10.1080\/19420862.2024.2443538"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1200\/JCO.2025.43.16_suppl.1019","article-title":"Sacituzumab tirumotecan (sac-TMT) as first-line treatment for unresectable locally advanced\/metastatic triple-negative breast cancer (a\/mTNBC): Initial results from the phase II OptiTROP-Breast05 study","volume":"43","author":"Yin","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"101707","DOI":"10.1016\/j.xcrm.2024.101707","article-title":"Phase 1a study of ESG401, a Trop2 antibody-drug conjugate, in patients with locally advanced\/metastatic solid tumors","volume":"5","author":"Wang","year":"2024","journal-title":"Cell Rep. Med."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"S91","DOI":"10.1016\/S0959-8049(22)01041-3","article-title":"The Trop-2-targeting antibody drug conjugate DB-1305 has higher antitumor activity and a potentially better safety profile compared with DS-1062","volume":"174","author":"Zhang","year":"2022","journal-title":"Eur. J. Cancer"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"2644","DOI":"10.1158\/1538-7445.AM2023-2644","article-title":"BL-M02D1, a novel Trop2-targeting ADC, demonstrates robust anti-tumor efficacy in preclinical evaluation","volume":"83","author":"Zhang","year":"2023","journal-title":"Cancer Res."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.2147\/OTT.S162447","article-title":"Targeting Trop-2 in solid tumors: Future prospects","volume":"12","author":"Zaman","year":"2019","journal-title":"OncoTargets Ther."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1158\/2159-8290.CD-21-0702","article-title":"Parallel genomic alterations of antigen and payload targets mediate polyclonal acquired clinical resistance to sacituzumab govitecan in triple-negative breast cancer","volume":"11","author":"Coates","year":"2021","journal-title":"Cancer Discov."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/s41523-025-00829-5","article-title":"Antibody\u2013drug conjugates in breast cancer: Mechanisms of resistance and future therapeutic perspectives","volume":"11","author":"Valle","year":"2025","journal-title":"npj Breast Cancer"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1038\/s41568-025-00869-w","article-title":"Unveiling the molecular and immunological drivers of antibody\u2013drug conjugates in cancer treatment","volume":"25","author":"Zippelius","year":"2025","journal-title":"Nat. Rev. Cancer"},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Khoury, R., Saleh, K., Khalife, N., Saleh, M., Chahine, C., Ibrahim, R., and Lecesne, A. (2023). Mechanisms of Resistance to Antibody-Drug Conjugates. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24119674"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1002\/cac2.12387","article-title":"Resistance to antibody-drug conjugates in breast cancer: Mechanisms and solutions","volume":"43","author":"Chen","year":"2023","journal-title":"Cancer Commun."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1200\/JCO.2023.41.16_suppl.1022","article-title":"Sequential use of antibody-drug conjugate after antibody-drug conjugate for patients with metastatic breast cancer: ADC after ADC (A3) study","volume":"41","author":"Abelman","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"7149","DOI":"10.1158\/1538-7445.AM2025-7149","article-title":"The role of TROP2 in the MoA of Dato-DXd and how it underpins the biologic rationale of the novel AI-guided biomarker TROP2 normalized membrane ratio","volume":"85","author":"Sung","year":"2025","journal-title":"Cancer Res."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1007\/s40291-025-00814-5","article-title":"Inter-Assay Variability of TROP2 Immunohistochemistry in Triple-Negative Breast Cancer: G. Cursano et al","volume":"29","author":"Cursano","year":"2025","journal-title":"Mol. Diagn. Ther."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"105828","DOI":"10.1016\/j.esmoop.2025.105828","article-title":"Survival outcomes and the role of DNADX ctDNA testing in patients treated with sacituzumab govitecan for metastatic breast cancer","volume":"10","author":"Morganti","year":"2025","journal-title":"ESMO Open"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"102720","DOI":"10.1016\/j.ctrv.2024.102720","article-title":"Clinical management, monitoring, and prophylaxis of adverse events of special interest associated with datopotamab deruxtecan","volume":"125","author":"Heist","year":"2024","journal-title":"Cancer Treat. Rev."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1158\/1535-7163.MCT-24-0267","article-title":"Potential Mechanisms of Interstitial Lung Disease Induced by Antibody\u2013Drug Conjugates Based on Quantitative Analysis of Drug Distribution","volume":"24","author":"Koganemaru","year":"2025","journal-title":"Mol. Cancer Ther."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1038\/nrc1977","article-title":"Topoisomerase I inhibitors: Camptothecins and beyond","volume":"6","author":"Pommier","year":"2006","journal-title":"Nat. Rev. Cancer"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/s41580-020-0214-3","article-title":"The tubulin code and its role in controlling microtubule properties and functions","volume":"21","author":"Janke","year":"2020","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1002\/pds.4297","article-title":"Good practices for real-world data studies of treatment and\/or comparative effectiveness: Recommendations from the joint ISPOR-ISPE Special Task Force on real-world evidence in health care decision making","volume":"26","author":"Berger","year":"2017","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/S0140-6736(04)17670-8","article-title":"External validity of randomised controlled trials: \u201cTo whom do the results of this trial apply?\u201d","volume":"365","author":"Rothwell","year":"2005","journal-title":"Lancet"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1007\/s00228-025-03876-w","article-title":"A meta-analysis and systematic review of the first Trop-2-targeting antibody\u2013drug conjugate (sacituzumab govitecan) in treating metastatic breast cancer","volume":"81","author":"Wang","year":"2025","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1001\/jamaoncol.2022.7476","article-title":"Clinicopathologic characteristics and prognosis of ERBB2-low breast cancer among patients in the national cancer database","volume":"9","author":"Peiffer","year":"2023","journal-title":"JAMA Oncol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2203690","article-title":"Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer","volume":"387","author":"Modi","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1038\/s41591-023-02478-2","article-title":"Trastuzumab deruxtecan in metastatic breast cancer with variable HER2 expression: The phase 2 DAISY trial","volume":"29","author":"Mosele","year":"2023","journal-title":"Nat. Med."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"5550","DOI":"10.1200\/JCO.23.00882","article-title":"Patritumab deruxtecan (HER3-DXd), a human epidermal growth factor receptor 3\u2013directed antibody-drug conjugate, in patients with previously treated human epidermal growth factor receptor 3\u2013expressing metastatic breast cancer: A multicenter, phase I\/II trial","volume":"41","author":"Krop","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"S474","DOI":"10.1016\/j.annonc.2021.08.542","article-title":"259P Weekly ladiratuzumab vedotin monotherapy for metastatic triple-negative breast cancer","volume":"32","author":"Tsai","year":"2021","journal-title":"Ann. Oncol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"S336","DOI":"10.1016\/j.annonc.2023.09.558","article-title":"381O First-in-human\/phase I trial of HS-20089, a B7-H4 ADC, in patients with advanced solid tumors","volume":"34","author":"Wu","year":"2023","journal-title":"Ann. Oncol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1007\/s11684-024-1072-8","article-title":"Unlocking the potential of bispecific ADCs for targeted cancer therapy","volume":"18","author":"Zeng","year":"2024","journal-title":"Front. Med."}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/33\/2\/92\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T13:15:23Z","timestamp":1770124523000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/33\/2\/92"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,3]]},"references-count":85,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,2]]}},"alternative-id":["curroncol33020092"],"URL":"https:\/\/doi.org\/10.3390\/curroncol33020092","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,3]]}}}